Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar and Sintilimab with Chemotherapy in Advanced Non-squamous NSCLC
NCT04063449Unknown
- Start
- Aug 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of sintilimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms). Primary endpoints: Progression-Free Survival at 36 months and Overall Survival at 36 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04063449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063449.